Baxdrostat

BAXFENDY

Open Baxdrostat in the interactive console ↗

Baxdrostat ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Baxdrostat ballicule

Baxdrostat BAXFENDY mascot mnemonic cartoon — Visual mnemonic: Baxdrostat mascot
**“Backster’s fender static”**

What it isAldosterone synthase inhibitor; resistant hypertension.

Why this oneBlocks aldosterone production rather than its receptor, avoiding spironolactone's antiandrogen effects.

What limits itHyperkalemia requires monitoring and combination with other potassium-raising drugs needs caution; long-term outcome data remain limited.

Baxdrostat molecular structure (skeletal formula) — Molecular structure: Baxdrostat

FDA-approved for

hypertension (2026)

Principal riskHyperkalemia; limited long-term data

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

FDA label

Read the full label on DailyMed ↗

NO BOXED WARNINGS

FDA dosing	Population	Start	Target	Max
Hypertension not adequately controlled (add-on)	Adult	2 mg QD (1 mg QD if increased risk of hyperkalemia or hyponatremia)	2 mg QD	2 mg QD

Renal No adjustment if eGFR ≥45 mL/min (unless at increased hyperkalemia risk); not established for eGFR <45

Hepatic Undefined

Instructions

Swallow tablets whole; do not cut, crush, or chew
Take with or without food
Correct serum potassium and sodium abnormalities before initiation
Do not take a double dose if a dose is missed

Available strengths

tab 1, 2 mg

Cautions

Hyperkalemia — assess serum potassium before and during treatment; monitor more often if at risk (≥65 y, diabetes, CKD, K-raising drugs)
Hyponatremia — assess serum sodium before and during treatment
Decrease in eGFR (hemodynamic; reversible after discontinuation)

Adverse reactions

Hyperkalemia (10%)
Hypotension (4%)
Hyponatremia (3%)
Dizziness (3%)
Muscle spasms (3%)

Pregnancy No human data; animal embryo-fetal toxicity at high exposures; clinical significance unclear

Lactation No human data; baxdrostat transfers to rat milk

Cost

Baxdrostat (BAXFENDY)

Strength		#/mo	generic $/mo	CostPlus
1 mg	tab	30 qd		not offered
2 mg	tab	30 qd		not offered

NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Baxdrostat is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2040 est.

Open Baxdrostat in the interactive console ↗

Memory aids: interaction avatars

CYP3A4 substrate

Open Baxdrostat in the interactive console ↗

Self-check

How does baxdrostat differ from spironolactone’s target?
Blocks aldosterone production, not its receptor.
What electrolyte requires monitoring with baxdrostat?
Potassium; hyperkalemia risk.